Degussa sells Proligo nucleic acid Group to Sigma-Aldrich

18-Feb-2005

Degussa AG has sold the Proligo Group to Sigma-Aldrich Corporation for an undisclosed purchase price. Completion of the transaction remains subject to the approval of the German Federal Anti-Trust Office (Bundeskartellamt).

Annual sales at Proligo, which employs around 300 staff worldwide, totaled 30.9 million euros in 2004. Proligo operates in the field of nucleic acids and oligonucleotide synthesis, with sites in Hamburg, Paris, Boulder, Singapore, Kyoto and Lismore/Australia.

Ranking sixth in the oligonucleotides market Proligo does not have the opportunities to achieve a leading position through its own resources. Moreover, this market is expected to face heavy consolidation. As a result, Degussa has been evaluating strategic options for Proligo over the past few months.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances